Salarius Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

DCOY$1.11+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Nine Months EndedSeptember 30
	2025	2024
Operating activities
Net loss	$(3,540,825)	$(4,111,844)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,318	3,318
Equity-based compensation expense	79,535	222,685
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(502,224)	506,888
Accounts payable	27,132	(437,052)
Accrued expenses and other current liabilities	242,364	33,186
Net cash used in operating activities	(3,690,700)	(3,782,819)
Investing activities
Short Term Promissory Note	(200,000)	—
Net cash used in investing activities	(200,000)	—
Financing activities
Proceeds from issuance of equity securities, net	6,487,718	1,526,460
Payments on note payable	(221,866)	(359,522)
Net cash provided by (used in) provided by financing activities	6,265,852	1,166,938
Net decrease in cash and cash equivalents	2,375,152	(2,615,881)
Cash and cash equivalents at beginning of period	2,434,528	5,899,910
Cash and cash equivalents at end of period	$4,809,680	$3,284,029
Supplemental disclosure of cash flow information:
Non-cash investing and financing activities:
Cash paid for interest	$5,800	$12,064
Accrued issuance costs for issuance of equity securities	290,058	—
Insurance premium financed by note payable	—	398,728

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.